Capricor Therapeutics expresses confidence in the FDA's forthcoming decision on Deramiocel.

CAPR · Capricor Therapeutics Inc.

The AI's read

Capricor says it's actively engaged with the FDA on the Deramiocel BLA and has a launch-ready GMP facility. They addressed a single Form 483 and report $237.9 million cash. The market responded with a ~67.7% surge and RSI ~70 on huge volume. That size move suggests much of the approval optimism is already priced. Our take: neutral. We need concrete FDA feedback or inspection timing before leaning bullish again.